


**PMF**

**Pharmaceutical  
Microbiology  
Forum**



# PMF NEWSLETTER

**A Publication of the Pharmaceutical Microbiology Forum  
DISTRIBUTED INTERNATIONALLY**

**PURPOSE:** To provide a forum for discussion of microbiology issues in the pharmaceutical and related industry. The information contained in this newsletter includes the professional opinions of individuals and does not represent the policies or operations of any corporation or government agency to which they may be associated. *PMF Newsletter* is intended to serve as an open forum. The information in *PMF Newsletter* is solely for informational purposes and is developed from sources believed to be reliable. Statements expressed constitute current opinions derived through analysis of available information and professional networking. Articles or opinions are for information only to stimulate discussion and are not necessarily the views of the PMF board or regulatory agencies. The *PMF Newsletter* cannot make any representations as to the accuracy or completeness of the information presented and the publisher cannot be held liable for errors.

Volume 12, Number 3 March, 2006

## A Mixed Bag

### In This Issue:

Editor's Message	1
<u>The Harmonization of the Microbial Limits Tests - Enumeration</u> Scott Sutton	2
<u>483 Alerts</u> - Richard Almond	4
<u>The Bacterial Endotoxin Summit</u>	4
<u>Microrite's BactiSpell 2006</u> - Ziva Abraham	5
<u>USP Corner</u>	6
<u>Internet Addresses</u>	9
<u>Upcoming Events</u>	9
<u>Discussion List Update</u>	9
<u>2005 Bibliography</u> - Scott Sutton	10

This month's newsletter is a mix of topics. To start off, there is a review of the methodology for Microbial Limits Tests (Enumeration) comparing critical aspects of the current USP and Pharm. Eur. Tests with the published draft of the Harmonized document. This is very current, as the PDG approved a final harmonized document last November, one that is reported to be virtually identical to the draft version. This is the first of three articles on the harmonized documents that will appear in the next few months.

The "483 Alerts" column reappears this month. A very popular feature of the *PMF Newsletter*, Rich Almond provides a compilation of observations of concern to microbiologists. This is followed by a review of the recent PMF Bacterial Endotoxin Summit, an event that was very well attended and received.

Ziva Abraham of Microrite provides the *PMF Newsletter* readership with a bonus this month. Along with this issue of the PMF Newsletter is a copy of the word list for BactiSpell ver. 2006 (it arrived as a separate attachment to your Email). The file is zipped—if you do not have a copy of WinZip you may get a free evaluation copy from <http://www.winzip.com>. The word lists provide custom dictionaries for MS Office programs that are specific for microbiology.

Finally, a bibliographic listing of relevant articles that appeared in 2005 is provided. This is not presented as an exhaustive list, and I apologize in advance to those I missed, but it may be useful to some. If you have an article that should have appeared, please send me a PDF copy of the article. I will put out an update later in the year if there are many missed.

The *PMF Newsletter* keeps on growing. This month's edition will be directly distributed to 5,000 subscribers in over 60 countries. Please recommend this publication to your colleagues.

Scott Sutton, Ph.D.  
Editor, *PMF Newsletter*

### Important Links:

Information on the PMFList at <http://www.microbiol.org/pmflist.htm>

Past Issues of the *PMF Newsletter* at <http://www.microbiologyforum.org/news.htm>

### Pharmaceutical Microbiology Forum (PMF) 2006 Editorial Board

#### President/Editor-in-Chief:

Scott Sutton, Ph.D. Vectech Pharmaceutical Consultants, Inc., USA

#### Editorial Board:

Ziva Abraham, Microrite, Inc., USA  
Phil Geis, Proctor-Gamble, CTFA, USA  
Klaus Haberer, Ph.D., Ph. Eur., Germany  
Karen McCullough, Roche Labs, LAL User's Group, USA  
Paul Priscott, Ph.D., AMS Labs, Australia  
Eric Strauss, Teva Pharmaceuticals, Israel



The PMF gratefully acknowledges the contributions of:

- Vectech Pharmaceutical Consultants, Inc. (<http://www.vectech.com>)
- High Peaks Associates, Inc. (<http://www.highpeaks.us>)

The *PMF Newsletter* is published by the Pharmaceutical Microbiology Forum. Copyright ©2006 by the Pharmaceutical Microbiology Forum. All Rights Reserved. Send all inquires, letters, and comments to [scott.sutton@microbiol.org](mailto:scott.sutton@microbiol.org)

## The Harmonization of the Microbial Limits Test - Enumeration

Scott Sutton, Ph.D.  
Vectech Pharmaceutical Consultants

The USP and the European Pharmacopoeia (EP, Pharm Eur) Microbial Limits Tests are in the final stages of harmonization. They were signed off to Stage 6A at the November, 2005 meeting of the Pharmacopoeial Discussion Group (PDG) held in Chicago, IL USA (USP 2006a). However, the signed-off versions have yet to be published. This makes the description of the test a bit difficult, as the current tests will be disappearing, and the final, harmonized test is not yet public knowledge. However, we do know that the harmonized tests do not differ greatly from the drafts published in 2003 (USP 2003a, USP 2003b, USP 2003c), and so we will use those drafts as the description of the finalized test.

The Microbial Limits Tests are actually two chapters in the current USP:  
Current USP <61> Microbial Limits Tests (USP 2006b) and <1111> Microbiological Attributes of Nonsterile Pharmaceutical Products (USP 2006c). This will be modified in the harmonized version to mirror the European format:

### Stages of the PDG Process

1. Identification of the item to be harmonized
2. Investigation into existing texts
3. Proposal for Expert Committee Review
4. Official Inquiry  
This is the version published in the *Pharmacopoeial Forum* or *PharmEuropa* for public comment
5. Consensus  
5A – Provisional  
This is the coordinating pharmacopoeia's proposal for consensus. If all three agree, it goes on to 5B, otherwise work continues for consensus  
5B – Draft Sign-off
6. Regional Adoption and Implementation  
6A – Adoption  
6B – Implementation
7. Inter-Regional Implementation

**Table 1: Harmonized Chapter Numbering Scheme**

USP	EP
<61> Microbiological Examination Of Nonsterile Products: Microbial Enumeration Tests	2.6.12 Microbiological Examination Of Nonsterile Products: Microbial Enumeration Tests
<62> Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms	2.6.13 Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms
<1111> Microbiological Quality of Nonsterile Pharmaceutical Products	5.1.4 Microbiological Quality of Nonsterile Pharmaceutical Products

This review will only address the microbial enumeration portions of the harmonization effort – that which will become USP chapter <61> and Pharm. Eur. chapter 2.6.12.

The microbial enumeration test is a basic, simple design to count the number of CFU in a nonsterile product or raw material. The preferred method is to put the material into solution and then plate aliquots to determine the CFU/gram (or mL) of initial material. If the product cannot be put into solution, there are provisions to use the Most Probable Number method (MPN – see FDA BAM website). The method of plating can be either pour plate, spread plate or the filtration of material and then placing the membrane filter on the surface of an agar plate. The membrane filtration method should only be used when there are few expected colony forming units in the material to be tested as it is a good method to test a large volume of liquid, but can

only count up to approximately 100 CFU/membrane.

The harmonized method provides a great deal more detail than any of the current pharmacopoeial methods in terms of demonstration of method suitability (validation of the method) and in terms of media growth promotion.

The demonstration of method suitability should be performed using the challenge organisms listed (see Table 2 below) in accordance with the recommendations found in USP chapter <1227> (USP 2006d). Growth promotion is an area of some ambiguity in the compendial text. Although media growth promotion is not described in the tests, demonstration of media suitability is required, and the draft USP Chapter <1117> (USP 2004) provides assistance in designing the studies using 10-100 CFU of the challenge organisms (also see

*(Continued on page 3)*

(Continued from page 2)

Application Note on this topic).

A major concern of many QC workers is if the changes in the harmonized chapter will necessitate revalidation of existing assays to meet the requirements of the harmonized test. There are several considerations that might lead to revalidation – a required change in media, in volume of material required for testing, in general testing conditions. It is difficult to determine whether all product types would require revalidation, and so a summary table is provided (Table 2) describing the critical aspects of the current Microbial Limits Tests (Enumeration) and the draft harmonization text. The summaries provided in Table 2 are only meant as an aid, the decision as to whether or not revalidation is necessary rests with each individual facility for their particular products.

## References:

- EP. 2006. 5.1.3 Efficacy of Antimicrobial Preservation. *Pharm Eur.* 5.0:447-449
- FDA BAM (Bacterial Analytical Manual *Online*) website - <http://www.cfsan.fda.gov/~ebam/bam-toc.html>. The second appendix to this document is an excellent tutorial on MPN methods. This can be found at <http://www.cfsan.fda.gov/~ebam/bam-a2.html>
- USP. 2003a. <61> Microbiological Examination Of Nonsterile Products: Microbial Enumeration Tests. *Pharm Forum.* 29(5):1714-1722.
- USP. 2003b. <62> Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms *Pharm Forum.* 29(5):1722-1733
- USP. 2003c. <1111> Microbiological Quality of Nonsterile Pharmaceutical Products *Pharm Forum.* 29(5):1733-1735
- USP. 2004. <1117> Microbiological Best Laboratory Practices. *Pharm Forum.* Sept/Oct 2004. 30(5):1713-1721.
- USP. 2006a. <1196> Pharmacopeial Harmonization. USP 29:3031-3035
- USP. 2006b. <61> Microbial Limits Tests USP 29:2503-2508
- USP. 2006c. <1111> Microbiological Attributes of Nonsterile Pharmaceutical Products USP 29:2969
- USP. 2006d. <1227> Validation of Microbial Recovery from Pharmacopeial Articles. USP 29:3053-3055

(Continued on page 6)



[Click Here](#) for high-impact Awareness gifts

A great source for microbiology-related ties,  
scarves and hats

## 483 Alerts

Richard Almond, Synthon Corp.

### **Failure to assure each drug product is free of objectionable microorganisms throughout their expiration dating period. [21 CFR 211.166 (a)]**

Anti-microbial preservative effectiveness testing conducted on finished drug products are inadequate as it does not assure that the anti-microbial preservatives formulated into your prescription, oral-liquid drug products, are effective in inhibiting the growth of objectionable microorganisms throughout the expiration-dating period of your drug products. In order to demonstrate the effectiveness of the preservatives added to your multi-dose prescription liquid products, appropriate challenge of your preservatives must be conducted.

Our investigator found that in addition to the lack of adequate preservative effectiveness testing, no microbiological testing of stability samples was conducted as required in your firm's stability protocols. The investigator was informed that your firm is considering removing the microbiological specifications from the protocols. We wish to point out that you are required to conform to the stability testing protocol approved by your quality unit and any deviation from the protocol should be approved by your quality unit and documented with an appropriate scientific rationale. We regard the failure to conduct appropriate preservative or microbiological testing to be a serious CGMP deviation because of the potential hazard microbiologically contaminated drug products can pose to patients.

### **Failure to establish written procedures for the cleaning and maintenance of manufacturing equipment, including utensils, used in the processing, packing or holding of a drug product. [21 CFR 211.67 (b)]**

Your firm has still not performed cleaning validation for several pieces of manufacturing equipment used to manufacture a variety of different prescription drug products. For example, cleaning validation studies for the semi-automatic filling machine, 35 liter stainless steel mixing pot and hand mixing utensils have not been performed. Therefore, there is a lack of assurance that cross contamination does not occur between drug products manufactured sequentially with the same equipment. Additionally, a microbiological assessment of the effectiveness of your cleaning agent was not

### **Failure to have control systems necessary to prevent contamination during the course of aseptic processing operations, including an air supply filtered through high-efficiency particulate air [redacted] filters under positive pressure [21 CFR 211.42(c)(10)(iii)]. The manufacture of your ophthalmic drug products is not conducted in a controlled room environment or under appropriate [redacted] filtered air supply necessary to prevent contamination.**

### **Failure to collect, maintain, and identify reserve samples of each lot of active ingredient and each lot of finished drug product manufactured for one year after the expiration date of the drug product [21 CFR 211.170(a) & (b)].**

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed in accordance with 21 CFR 211.113(b).

Specifically,

Not all personnel who enter the sterile core are monitored each day. Maintenance and cleaning personnel are only monitored during the annual gowning re-certification and/or semi-annual media fills. Additionally, not all operators who gown and enter the sterile core to assemble equipment or unload the autoclave are monitored.

## The 2006 PMF Bacterial Endotoxin Summit

What a great conference! The 2006 PMF Bacterial Endotoxin Summit (BES) was held February 15<sup>th</sup> and 16<sup>th</sup> in Philadelphia, PA and addressed the issues of the BET ranging from the basic to the advanced and future technologies.

Karen McCullough of Roche Molecular Systems moderated the conference, providing commentary and perspective from her years of experience both from a corporate setting and as a consultant. She did a fantastic job of putting together an outstanding faculty for this event.

Michael Dawson of Associates of Cape Cod gave an industry perspective on compliance documents, on problems peculiar to the test in terms of inhibition/enhancement and on setting specifications for finished products and raw materials.

Ronald Berzofsky, Ph.D. represented Cambrex Bio Science (now with GeneChoice) provided context to the discussion with a strong overview of the science underlying the BET. He also presented on photometric methods, depyrogenation considerations, and process validations. Foster Jordan of Charles River Endosafe provided a background on the gel clot method, described methods for setting endotoxin limits and performing cleaning validation. Robert Mello, Ph.D. of FDA provided a perspective on regulatory and compliance directions under consideration at the Agency.

All speakers provided commentary throughout the conference (frequently on each other's topics!) and were accessible at breaks and during the reception for further conversation. The meeting ended with each speaker providing an glimpse of what was new in the industry from their perspective.

The reception was a big hit. We had a special visitor, "Benjamin Franklin" who dropped by to celebrate his 300<sup>th</sup> birthday with the conference attendees. Ben was introduced to the reception by Karen, and spent over an hour mingling with the attendees, discussing history, philosophy, and poli-



Benjamin Franklin (center) with the BES speakers: (L-R) Robert Mello, Michael Dawson, Ronald Berzofsky, Karen McCullough, Foster Jordan

tics.

The conference was well received by the attendees. Everyone took away valuable information from the speakers, and in addition the conference materials included a complete copy of the presentations as well as a copy of the book "Endotoxins: Pyrogens, LAL Testing, and Depyrogenation (Drugs and Pharmaceutical Science, Vol. 111)" by Kevin L. Williams (ed) Marcel Dekker Publishers. (2001) for future review.

Comments received on the event:

"Please do this AGAIN! I was very pleased with the scope of the discussions. It was nice to address technical items but with more focus on Quality and regulatory issues. I have plateaued on all the training offered recently and I feel this time I actually learned something new and came away with a new perspective and a new direction in which to move our lab and additional tools for consulting our sponsors."

"The conference was very beneficial for discussing endotoxin issues, etc. in the industry. All of the speakers were very approachable, presentation materials were excellent. I liked that it was a very informal setup."

"Very interesting in so many areas. So informative. ... The reception was a great opportunity to network."

"Thought the conference was very well organized, great information, very useful. I was glad that there was a focus on the details (calculating MVD, etc) rather than a high-level overview. I will be able to use this information in my laboratory. Overall a great conference – looking forward to the next one!"

"Very good, easy to follow overview topics; Good hands-on practice with current/important industry topics. Venue choice excellent."

"I am new to the LAL Assay – however involved with microbiology for some time. I found this meeting and sessions very useful and informative. Plenty of opportunity to participate and I felt I was hearing from the best in the industry."

"Good mix of presentations! It would have been nice to have this in a more central location, or an east & west coast summit."

"Excellent conference! If it's possible to add to future summits I would like to see more of the math used with BET and Pyrogen testing!"

As we're always looking to improve on a good thing, the organizers have taken participant suggestions seriously, and are considering adding break out sessions for problem solving, more opportunities for round table discussion, a new and exciting location and more math (!)"

*(Continued on page 5)*

(Continued from page 4)

Clearly this conference was a strong addition to the year, and one that PMF was glad to be able to bring this event to the industry. We would like to thank the organizers – High Peaks Associates (<http://www.highpeaks.us>) for the fantastic job they did “behind the scenes” both in the preparation and execution of the conference leaving the scientists able to concentrate on the content, rather than the machinery of the conference.

The Bacterial Endotoxin Summit will be presented again through the Pharmaceutical Microbiology Forum, and we look forward to seeing you at the next one.

### USP Corner

#### **Revalidation of Microbial Limits Tests?**

The Microbial Limits chapters were finalized by the PDG (Pharmacopeial Discussion Group, made up of representatives of the JP, EP, and USP) in November of 2005. This month is the first of three installments on the Microbial Limits Tests. These installments will cover:

- Microbial Enumeration Tests
- “Absence of Specified Microorganisms” Tests
- What is the Difference Between “Specified” and “Objectionable” Microorganisms?

The first two installments will focus on **the need to revalidate product tests**. The final installment in this series will look at FDA concerns as they relate to non-sterile finished products, and the compendial perspective.

---

Any questions concerning USP documents should be sent to Radhakrishna (Radha) Tirumalai, Ph.D. You can reach Dr. Tirumalai at: (301) 816-8339, via mail at United States Pharmacopeia, 12601 Twinbrook Parkway, Rockville, MD 20852-1790 or via e-mail at [RST@USP.org](mailto:RST@USP.org). You can write representing your company, or as an individual scientist.

### **Microrite’s BactiSpell 2006**

In the year 2000, after 25 years of being a microbiologist in clinical and industry settings, I realized that I could not spell bacterial names correctly. At first I thought it was just me, but reflecting on the spelling errors in various reports, laboratory data and results I had reviewed, I plunged into the project of creating a spellchecker that will help me and many others like me. It was a long drawn process of collecting names of bacteria from known resources as well as references and then verifying them against Bergey’s Manual. I was surprised to find that many names were spelled differently in different references. Of course, I chose Bergey’s as the Gold Standard. This collection of words was then compiled into a software package. The software was called Bactispell. Long hours of programming and Beta testing were spent to ensure that the software matched the Genera with their correct species names. There were many cases when the Genera and the species were spelled the same way. The software was programmed to recognize these special instances. Essentially the software recognized the Genera and capitalized the first letter, if it was not capitalized and recognized the species names and un-capitalized them. The program followed this procedure as it went through the document, and concurrently it italicized all the bacterial names.

This software was sold on Microrite’s website for Office 95 and then upgraded to work with Office 98. It was when Office 2000 was released that Bactispell was discontinued due to inability to keep up with the error messages while installing, and the trouble shooting efforts that it demanded for different operating systems. The advanced security systems installed on personal computers increased software support beyond what we could support.

I offered the text version to the microbiology community for free use in the PMF newsletter in 2002.

Dr. Scott Sutton recently decided to add more technical terms to the word list before we offered it for free download on PMF and Microrite websites. The three word lists Bactispell 1; Bactispell 2 and Bactispell 3 are extensive, and can help you spell check bacterial names and technical terms.

Please take advantage of this tremendously helpful tool and save time by not checking references for correct spellings.

Ziva Abraham  
Microrite, Inc.  
<http://www.microrite.com>

**Come Visit Our Website at**  
<http://www.microbiologyforum.org>

**Archives of the PMF Newsletter at**  
<http://www.microbiologyforum.org/news.htm>

Continued from Page 3

**Table 2 – Aspects of the Current and Harmonized Microbial Limits Tests (Enumeration)**

Issue	USP <61>	EP Chapter 2.6.12	Harmonized
Media Growth Promotion – Organisms for Trypti- case Soy	<i>Staphylococcus aureus</i> <i>Escherichia coli</i> <i>Pseudomonas aeruginosa</i> <i>Salmonella</i>	<i>Staphylococcus aureus</i> ATCC 6538 (NCIMB 9518, CIP 4.83) <i>Escherichia coli</i> ATCC 8739 (NCIMB 8545, CIP 53.126) <i>Bacillus subtilis</i> ATCC 6633 (NCIMB 8054, CIP 5262)	<i>Staphylococcus aureus</i> ATCC 6538 (NCIMB 9518, CIP 4.83, NBRC 13276) <i>Pseudomonas aeruginosa</i> ATCC 9027 (NCIMB 8626, CIP 82.118, NBRC 13275) <i>Bacillus subtilis</i> ATCC 6633 (NCIMB 8054, CIP 5262, NBRC 3134) <b>Note</b> – detail provided on method of preparation and culture
Media Growth Promotion – Organisms for Sabo- raud Dextrose	Not mentioned	<i>Candida albicans</i> ATCC 10231 (NCPF 3179, IP 48.72) <i>Aspergillus niger</i> ATCC 16404 (IMI 149007, IP 1431.83)	<i>Candida albicans</i> ATCC 10231 (NCPF 3179, IP 48.72, NBRC 1594) <i>Aspergillus niger</i> ATCC 16404 (IMI 149007, IP 1431.83, NBRC 9455) <b>Note</b> – detail provided on method of preparation and culture
Media Growth Promotion – Methodology	Not detailed	Use less than 100 CFU per media Counts must be within five-fold of control (95% confidence interval for MPN)	Use less than 100 CFU per media Counts must be within 50% of control (95% confidence interval for MPN)
Media Sterility Check	Not detailed	Combined with Negative Product Control	Recommended
Suitability of the Count- ing Method	Inoculate diluted specimens of the product to be tested with challenge organisms May stop validation effort after sufficient effort has shown a particular organism cannot be recovered.	Must show recovery in presence of product	Preparation of Test Strains detailed Use less than 100 CFU of challenge organism Instruction provided on the neutralization of antimicrobial activity Recovery must be within 50% of control May stop validation effort after sufficient effort has shown a particular organism cannot be recovered.

**Table 2 – Aspects of the Current and Harmonized Microbial Limits Tests (Enumeration) (cont)**

Issue	USP <61>	EP Chapter 2.6.12	Harmonized
Sampling Plan	Not detailed	Must follow well-defined sampling plan Batch size Health hazard Product Characteristics Expected Level of Contamination	Sampling plan not detailed Discussion of modifications to sample volume: Active agents in low concentrations Bulk materials Small batches
Sample Volume	10 grams	10 grams	10 grams
Categories	Water soluble Water-immiscible fluids, ointments, creams, waxes Fluid in aerosol form	Water-soluble products Non-fatty Products insoluble in water Fatty Products Transdermal Patches	Water-soluble products Non-fatty Products insoluble in water Fatty Products Fluids or solids in aerosol form Transdermal Patches
Methodology – Membrane Filtration	Not listed	Transfer 1 gram to each of two filters (0.45 um nominal pore size), filter Three 100 mL washes One filter on TSA, one on SDA Incubate TSA Plate at 30-35°C for 5 days Incubate SDA Plate at 20-25°C for NMT 5 days Count plates with NMT 100 CFU	Transfer validated amount to two filters Wash each filter by validated method Total Aerobic Microbial Count (TAMC) filter is placed on TSB, incubated at 30-35°C for 3 to 5 days Total Yeast and Mold Count (TYMC) filter is placed on SDA, incubated at 20-25°C for 5 to 7 days
Methodology – Plate Count: Pour Plate	Add 1 mL of sample at appropriate dilution to 9 cm diameter petri dish. Add 15-20 mL liquified agar (TSA and SDA) Plate in duplicate Incubate TSA at 30-35°C for 18 to 72 hours for Total Aerobic Microbial Count; Incubate SDA at 20-25°C for 5-days for Total Combined Yeast and Mold Count	Add 1 mL of sample at appropriate dilution to 9 cm diameter petri dish. Add 15-20 mL liquified agar (TSA and SDA) Plate in duplicate Incubate as above Count plates with not more than 300 CFU	Prepare sample by a method shown to be suitable. Plate 1 mL in at least duplicate on TSA and SDA Incubate TSA plates at 30-35°C for 3 to 5 days Incubate SDA plates at 20-25°C for 5 to 7 days Count from plates with less than 250 for TAMC, less than 50 CFU for TYMC

Continued from Page 7

**Table 2 – Aspects of the Current and Harmonized Microbial Limits Tests (Enumeration) (cont)**

Issue	USP <61>	EP Chapter 2.6.12	Harmonized
Methodology – Plate Count: Spread Plate	Not listed	Add 0.1 mL of sample at appropriate dilution to 9 cm diameter petri dish containing agar (TSA and SDA) Plate in duplicate Incubate as above Count plates with not more than 300 CFU	Prepare sample by a method shown to be suitable. Plate 0.1 mL in at least duplicate on TSA and SDA by spreading on surface of prepared plates Incubate as above Count from plates with less than 250 for TAMC, less than 50 CFU for TYMC
Methodology – Most Probable Number (MPN)	Assemble 14 tubes of TSB (9 mL each Do a 10-fold dilution series of the sample (in triplicate) into twelve of the tubes Incubate all 14 tubes Negative controls must remain clear Read results from table	Use only for bacteria Prepare at least three ten-fold dilutions in series Inoculate three aliquots of each dilution 1g or 1mL samples into each of three tubes of 9-10 mL TSB Incubate 30-35°C for 5 days Read results from table provided	Prepare sample by a method shown to be suitable. Incubate tubes 30-35°C for 3 to 5 days Read results from table provided
Additional Controls	None	Use sterile sodium chloride-peptone solution pH 7.0 as test preparation to test: Sterility of Medium Sterility of Diluent Aseptic Performance of the test	Use Sterile Diluent as the test preparation for each batch of diluent to verify testing conditions.
Interpretation of Results	Must meet specs Retest allowed using 25 gram sample	Must be within five-fold of specification for product	Must be within two-fold of specification for product



## Upcoming Events

### March

- 13<sup>th</sup> -14<sup>th</sup> **Species and speciation in micro-organisms**  
Location: The Royal Society, 6-9 Carlton House Terrace, London SW1Y 5AG.  
Phone: 020 7451 2500  
Email: [events@royalsoc.ac.uk](mailto:events@royalsoc.ac.uk)  
Web Site: [www.royalsoc.ac.uk/events](http://www.royalsoc.ac.uk/events)
- 13<sup>th</sup> – 15<sup>th</sup> **Microbiology Course Series**
  - Validation of Microbiological Methods
  - Auditing QC Microbiology Laboratories
  - Water System Microbiology
  - Microbial Identification Methods
Location: San Francisco Bay Area  
Phone: 888-844-8561 (toll-free, North America)  
or +1 585-594-3336  
Email: [register@highpeaks.us](mailto:register@highpeaks.us)  
Web Site: <http://www.highpeaks.us/upcoming.htm>
- 19<sup>th</sup> – 22<sup>nd</sup> **Annual Conference of the Association for General and Applied Microbiology**  
Location: Friedrich-Schiller-University Jena, Germany  
Phone: +49(0)3641 35 33 15  
Email: [vaam@conventus.de](mailto:vaam@conventus.de)  
Web Site: <http://www.vaam.de>; <http://www.conventus.de/vaam>
- 23<sup>rd</sup> – 24<sup>th</sup> **Investigating Microbial Contaminations Course**  
Location: Caribe Hilton (San Juan, Puerto Rico) Phone: +1 408-445-0507  
Web Site: <http://www.microrite.com/>  
[Investigating\\_Microbial\\_Contaminations\\_Puerto\\_Rico\\_March\\_2006.pdf](http://www.microrite.com/Investigating_Microbial_Contaminations_Puerto_Rico_March_2006.pdf)
- 27<sup>th</sup> - 28<sup>th</sup> **2006 International Conference on Biocontainment Facilities**  
Location: St. Petersburg, FL  
Phone: 925-254-1744  
Email: [bill@tradelineinc.com](mailto:bill@tradelineinc.com)  
Web Site: <http://www.tradelineinc.com/bio>
- 27<sup>th</sup> - March 1 **Managing Risk in Aseptic Filling and Processing for Pharmaceutical and Biopharmaceutical Products**  
Location: London  
Website: <http://www.iir-events.com/IIR-Conf/page.aspx?id=246>
- 29<sup>th</sup> - 31<sup>st</sup> **The Environmental Monitoring and The Stability Technical Seminar and Workshop**  
Location: Hilton New York, NY  
Phone: 514-788-6023  
Web Site: <http://www.novaseminars.com>

### April

- 19<sup>th</sup> – 21<sup>st</sup> **Microbiology Course Series**
  - Validation of Microbiological Methods
  - Auditing QC Microbiology Laboratories
  - Water System Microbiology
  - Microbial Identification Methods
Location: San Juan, Puerto Rico  
Phone: 888-844-8561 (toll-free, North America)  
or +1 585-594-3336  
Email: [register@highpeaks.us](mailto:register@highpeaks.us)  
Web Site: <http://www.highpeaks.us/upcoming.htm>
- 24<sup>th</sup>–29<sup>th</sup> **PDA Annual Meeting**  
Location: Anaheim Marriott, Anaheim, CA.  
Web Site: <http://www.pda.org/annual2006>

### Offering In-House Courses on Microbiology/Aseptic Processing:

- The Microbiology Network/High Peaks Associates <http://www.highpeaks.us/in-house.htm>
- USP  
Contact Steven Paul ([stp@usp.org](mailto:stp@usp.org)) for information on the course “Fundamentals of Microbiological Testing”

### Discussion List Update

#### PMFList:

Number of Subscribers: 1,464  
Number of Countries: 52  
Number of Messages Last Month: 271

#### PSDGList:

Number of Subscribers: 777  
Number of Countries: 20

### Are you aware of our on-line discussion group?

Membership is FREE. To **join the PMFList**, visit <http://www.microbiol.org/pmflist.htm> and register.

A sister Email is devoted to topics in the **stability testing** of pharmaceuticals, medical devices and personal products. To **join the PSDGList**, visit <http://www.microbiol.org/psdglist.htm> and register.

You can ask, answer, or read questions and comments from your colleagues.

### Would you like to advertise in the PMF Newsletter?

Opportunities to present promotional material in exchange for support of the operation of the *PMF Newsletter* are available.

Please contact the editor for details.

## 2005 Bibliography

A listing of articles that may be of interest to the readership.

### Aseptic Processing

- Agalloco, J *et al.* 2005. Managing Aseptic Interventions. *Pharm Technol.* March:56-66
- Agalloco, J. 2005. Importance of Background Microbial Levels in the Manufacture and Testing of Sterile Products. *Pharm Technol.* 29(4):74-80
- Agalloco, J.. 2005. Managing Aseptic Interventions. *Pharm Technol.* 29(3):56 - 66
- Agalloco, J and J Akers. 2005. Aseptic Processing: A Vision of the Future. *Pharm Technol.* Aseptic Proc:s16-23
- Akers, J and J Agalloco. 2005. Risk Analysis for Aseptic Processing: The Akers - Agalloco Method. *Pharm Technol.* 29(11):74-88
- Colombo, A and P Sivertsson. 2005. Disposable Technologies Within Aseptic Processing. *Amer Pharm Rev.* 8(1):24-28
- CPMP. 2005. EMEA/CHMP/QWP/49313/2005 corr. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products. *CPMP.* \_\_\_\_\_
- Czarneski, MA and P Lorcheim. 2005. Isolator Decontamination Using Chlorine Dioxide Gas. *Pharm Technol.* 29(4):124-133
- DeSorbo, M.. 2005. Regulatory Report: Cultivating Contamination Control. *Contamn Control.* 1(1):30 - 31
- Eaton, T. 2005. Microbial Risk Assessment for Aseptically Prepared Products. *Amer Pharm Rev.* 8(5):46-51
- Friedman, RL. 2005. Aseptic Processing Contamination Case Studies and the Pharmaceutical Quality System. *PDA J Pharm Sci Tech.* 59(2):118-126
- Leo, F *et al.* 2005. Design, Development and Qualification of a Microbiological Challenge Facility to Assess the Effectiveness of BFS *PDA J Pharm Sci Tech.* 59(1):33-48
- Ljungqvist, B and B Reinmuller. 2005. Aseptic Production, Gowning Systems and Airborne Contaminants. *Pharm Technol.* Aseptic Proc:s30-s34
- MacDougall, K.. 2005. An Inside Look at Disposable Wipers. *Contamn Control.* Fall:40 - 42
- Mackler, S.. 2005. Particle Counts are Easy. *Contamn Control.* Fall:46 - 56
- Madsen, RE. 2005. Aseptic Processing: Minimizing Risk Through Technology. *Pharm Technol.* Aseptic Proc:s8-s9
- Meyer, D. 2005. Isolator Technology with the Patient in Mind. *Pharm Technol.* Aseptic Proc:s10-s16
- Montalvo, M. 2005. ISO 14644 Air Cleanliness Standards for a Large-Scale Aseptic Manufacturing Facility. *Amer Pharm Rev.* 8(6):16 - 21
- Oie, S. and A. Kamiya. 2005. Particulate and Microbial Contamination in In-Use Admixed Parenteral Nutrition Solutions. *Biol Pharm Bull.* 28(12):2268 - 2270
- Rudge, SR *et al.* 2005. Multi-tenant Facilities for Biotech and Pharmaceutical Companies. *Contamination Control.* 1(1):40-46
- Stockdale, D. 2005. Overview of Aseptic Fill/Finish Manufacturing - Part 2: Regulatory Requirements. *Amer Pharm Rev.* 8(4):40-45
- Stockdale, D. 2005. Overview of Aseptic Fill/Finish Manufacturing - Part 3: Process Validation. *Amer Pharm Rev.* 8(5):52-58
- Tidswell, E.. 2005. Risk-Based Approaches Facilitate Expedient Validations for Control of Microorganisms During Equipment Cleaning and Hold. *Amer Pharm Rev.* 8(6):28 - 33
- USP. 2005. <1116> Microbiological Control and Monitoring Environments used for the Manufacture of Healthcare Products. *Pharm Forum.* 31(2):524-549
- Verjans, B *et al.* 2005. A New Concept in Aseptic Filling: Closed-Vial Technology. *Pharm Technol.* Aseptic Proc:s24-s29

### Biofilm

- Bester, E., Wolfaardt, G., *et al.* 2005. Planktonic-Cell Yield of a Pseudomonad *Applied and Environmental Microbiology.* 71(12):7792 - 7798
- Chaw, K., Manimaran, M., *et al.* 2005. Role of Silver Ions in Destabilization of Intermolecular Adhesion Forces Measured by Atomic Force Microscopy in Staphylococcus Epidermidis Biofilms. *Antimicrob Agents Chemother.* 49(12):4853 -4859
- Chour, K-L *et al.* 2005. Molecular Analysis of Microbial Diversity in Advanced Caries. *J Clin Microbiol.* 43(2):843-849
- Heurlier, K *et al.* 2005. Quorum-Sensing-Negative (lasR) Mutants of *Pseudomonas aeruginosa* Avoid Cell Lysis and Death. *J Bacteriol.* 187(14):4875-4883
- Hunter, TC and TJ Beveridge. 2005. High-Resolution Visualization of *Pseudomonas aeruginosa* PAO1 Biofilms by Freeze-Substitution Transmission Electron Microscopy. *J Bacteriol.* 187(22):7619-7630
- Jefferson, KK *et al.* 2005. Use of Confocal Microscopy To Analyze the Rate of Vancomycin Penetration through *Staphylococcus aureus* Biofilms. *Antimicrob Agents Chemother.* 49(6):2467-2473

(Continued on page 11)

(Continued from page 10)

- Kreth, J., *et al.* 2005. Competition and Coexistence between *Streptococcus mutans* and *Streptococcus sanguis* in the Dental *J Bacteriol.* 187(21):7193 - 7203
- Kumamoto, C./Vinces, M.. 2005. Alternative *Candida albicans* Lifestyles: Growth on Surfaces. *Ann Rev Microbiol.* 59:113 - 133
- Leis, AP *et al.* 2005. Optically Transparent Porous Medium for Nondestructive Studies of Microbial Biofilm Architecture and Transport Dynamics. *Appl Environ Microbiol.* 71(8):4801-4808
- Macedo, AJ. 2005. Three Stages of a Biofilm Community Developing at the Liquid-Liquid Interface between Polychlorinated Biphenyls and Water. *Appl Environ Microbiol.* 71 (11):7301–7309
- Overhage, J *et al.* 2005. Expression of the *psl* Operon in *Pseudomonas aeruginosa* PAO1 Biofilms: PslA Performs an Essential Function in Biofilm Formation. *Appl Environ Microbiol.* 71(8):4407-4413
- Petersen, FC *et al.* 2005. DNA Binding-Uptake System: a Link between Cell-to-Cell Communication and Biofilm Formation. *J Bacteriol.* 187(13):4392-4400
- Pettit, RK *et al.* 2005. Microplate Alamar Blue Assay for *Staphylococcus epidermidis* Biofilm Susceptibility Testing. *Antimicrob Agents Chemother.* 49(7):2612-2617
- Resch, A *et al.* 2005. Differential Gene Expression Profiling of *Staphylococcus aureus* Cultivated under Biofilm and Planktonic Conditions. *Appl Environ Microbiol.* 71(5):2663–2676
- Sarkisova, S *et al.* 2005. Calcium-Induced Virulence Factors Associated with the Extracellular Matrix of Mucoid *Pseudomonas aeruginosa* Biofilms. *J Bacteriol.* 187(13):4327–4337
- Sharma, PK *et al.* 2005. Influence of Fluid Shear and Microbubbles on Bacterial Detachment from a Surface. *Appl Environ Microbiol.* 71 (7):3668–3673
- Simões, M., Pereira, M., *et al.* 2005. Effect of mechanical stress on biofilms challenged by

different chemicals. *Water Research.* 39:5142 - 5152

- Tidswell, EC. 2005. Bacterial Adhesion: Considerations Within a Risk-based Approach to Cleaning Validation. *PDA J Pharm Sci Tech.* 59(1):10-32
- Trotonda, MP *et al.* 2005. SarA Positively Controls Bap-Dependent Biofilm Formation in *Staphylococcus aureus*. *J Bacteriol.* 187(6):5790-5798
- Venugopalan, VP *et al.* 2005. Architecture of a Nascent *Sphingomonas* sp. Biofilm under Varied Hydrodynamic Conditions. *Appl Environ Microbiol.* 71(5):2677–2686
- Wales, A., Woodward, M., *et al.* 2005. Attaching-Effacing Bacteria in Animals. *J Comp Path.* 132:1 - 26
- Zara, S *et al.* 2005. FLO11-Based Model for Air-Liquid Interfacial Biofilm Formation by *Saccharomyces cerevisiae*. *Appl Environ Microbiol.* 71(6):2934-2939

#### Compendia

- Anon. 2005. USP Launches Monograph Campaign; Adopts "Flexible" Policy. *Pharm Processing.* Feb:42
- Bishara, RH *et al.* 2005. The USP Revision Process: Recommendations for Enhancements. *Pharm Forum.* 31(2):656-661
- Dabbah, R.. 2005. The Role of USP Microbiology Standards and Information in the Development, Formulation, Manufacturing and Marketing of Drugs and Biologicals. *Amer Pharm Rev.* 8 (3):18-23, 78
- Garfinkle, BD *et al.* 2005. The Development of Chapter <1235> Vaccines and Vaccine Test Methods. *Pharm Forum.* 31(5):1533-1538
- LeBlond, D *et al.* 2005. Revisiting the Notion of Singlet Testing Requirements. *Pharm Technol.* 29(6):86-85
- Martis, L., Patel, M., *et al.* 2005. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. *Lancet.* 365:588 - 594
- Morris, TS. 2005. United States Pharmacopoeia Activities in the Area of Vaccines, Virology and Immunology. *Vaccine.* 23:2311-2313

(Continued on page 12)

Internet Address	Description
<a href="http://www.microbes.info/">http://www.microbes.info/</a>	Microbiology information resources and links on microorganisms, bacteria, microbes, viruses, bacteriology, microbiology and virology by microbes.info.
<a href="http://www.bact.wisc.edu/Microtextbook/">http://www.bact.wisc.edu/Microtextbook/</a>	News, useful training information.
If you have found an Internet site that contains information of relevance to pharmaceutical microbiology, please let us know.	

(Continued from page 11)

- Reich, RR and H Patterson. 2005. USP <797>: How it Affects Medical Device Manufacturers. *Med Device Diag Indust.* 27(1):108-112
- Sutton, SVW *et al.* 2005. Activities of the USP Analytical Microbiology Expert Committee During the 2000-2005 Revision Cycle. *PDA J Pharm Sci Tech.* 59(3):157-176
- Torbeck, LD. 2005. In Defense of USP Singlet Testing. *Pharm Technol.* Feb:105-106
- Travis, P., Heck, K., *et al.* 2005. Compendial Calculations: Improving Calculations in USP-NF. *Pharm Forum.* 31(6):1749-1755
- Tuper, HG and BJ Tindall. 2005. Material Transfer Agreements of Culture Collections Threaten Prokaryote Taxonomy. *ASM News.* 71(6):259-260
- USP Staff. 2005. Comments on "Compendial Calculations: Improving the Calculations in USP-NF". *Pharm Forum.* 31(6):1756 - 1757
- Williams, RL. 2005. Good Work and True - USP Prepares for Convention 2005. *Pharm Technol.* Feb:88-89
- Williams, RL. 2005. US Pharmacopeia's Convention 2005. *Pharm Technol.* 29(4):164-166

### Cultures

- Hays, H., *et al.* 2005. A Novel and Convenient Self-Drying System for Bacterial Preservation. *J Microbiol Methods.* 63:29 - 35
- Morris, G.. 2005. The origin, ultrastructure, and microbiology of the sediment accumulating in liquid nitrogen storage vessels. *Cryobiology.* 50:231 - 238
- Truper, HG and BJ Tindall. 2005. Letter: Material Transfer Agreements of Culture Collections Threaten Prokaryotic Taxonomy. *ASM News.* 71(6):259-260
- Truper, HG. 2005. International Perspectives on Taxonomy: from the Past to the Future. *ASM News.* 71(6):273-277

### Disinfection

- AORN Staff. 2005. Recommended Practices for High-Level AORN *Journal.* 81(2):402 - 412
- Dettenkofer, M./Block, C.. 2005. Hospital Disinfection: Efficacy and Safety Issues. *Curr Opin Infect Dis.* 18:320 - 325
- Rutala, W., *et al.* 2005. The benefits of surface disinfection. *AJIC.* 33(7):434 - 435
- Sutton, SVW. 2005. Disinfectant Rotation - A Microbiologist's View. *Controlled Environments.* 8(7):9-14
- Valdramidis, V., Belaubre, N., *et al.* 2005. Deve-

lopment of Predictive Modelling Approaches for Surface Temperature and Associated Microbiological Inactivation During Hot Dry Air Decontamination. *Int J Food Microbiol.* 100:261 - 274

### Environmental Monitoring

- Booth, A.. 2005. Environmental Monitoring Practices for the Life Sciences. *Contamn Control.* Fall:41 - 45
- Buddemeyer, J. 2005. Selecting an Active Air Sampling Methodology. *Controlled Environments.* 8(7):19-23
- Butler, R.. 2005. One Size Does Not Fit All. *Contamn Control.* Fall:28 - 31
- Cardin, R.. 2005. Raising Both Ends of the EM Bar. *Amer Pharm Rev.* 8(3):36 - 40
- Der, EF *et al.* 2005. Comparative Evaluation of Three Active Air Samplers for the Monitoring of Airborne Microorganisms. *Pharm Technol.* 29(4):110-116
- Eaton, T. 2005. Microbial Risk Assessments for Pharmaceutical Products. *The Cleanroom Monitor S2C2.* 52:1 - 12
- Farrington, JK. 2005. Environmental Monitoring in Pharmaceutical Manufacturing - A Product Risk Issue. *Amer Pharm Rev.* 8(4):26-30
- Fijan, S., Šostar-Turk, S., *et al.* 2005. Implementing Hygiene Monitoring Systems in Hospital Laundries in Order to Reduce Microbial Contamination of Hospital Textiles. *J Hosp Infect.* 61:30 - 38
- Floyd, MM *et al.* 2005. Captured Diversity in a Culture Collection: Case Study of the Geographic and Habitat Distributions of Environmental Isolates Held at the American Type Culture Collection. *Appl Environ Microbiol.* 71(6):2813-2823
- Gaonkar, T., Geraldo, I., *et al.* 2005. An alcohol hand rub containing a synergistic combination of an emollient and preservatives: prolonged activity against transient pathogens. *J Hosp Infect.* 59:12 - 18
- Hallworth, M. 2005. Particle Monitoring Particulars. *Contamination Control.* 1(1):32-35
- Katayama, H *et al.* 2005. Establishment of Critical Contamination Risk Locations ("Hot Spots") in Environmental Monitoring by Means of Three-Dimensional Airflow Analysis and Particulate Evaluation. *PDA J Pharm Sci Tech.* 59(1):49-63
- Kelly, J. 2005. Pharmaceutical Industry Cleanroom Monitoring: Viable and Non-viable Particle Detection. *A2C2.* 8(1):10-13
- Kelly, J.. 2005. Microbiological Air Samplers and ISO 14698-1/2. *A2C2.* 8(5):8 - 11

(Continued on page 13)

(Continued from page 12)

- Leo, F., Poisson, P., *et al.* 2005. Impact of Blow/Fill/Seal Process Variables in Determining Rate of Vial Contamination by Air Dispersed Microorganisms. *PDA J Pharm Sci Tech.* 59 (5):320 - 331
- Mulligan, TR. 2005. Case Study: Reducing Foot and Wheel Contamination in a Pharmaceutical Setting. *A2C2.* 8(1):28-30
- One, J. 2005. An Approach to Developing a Microbial Environmental Control Program for Non-Sterile Pharmaceutical Manufacturing. *Amer Pharm Rev.* 8(4):32-39
- Otondo, W. 2005. Environmental Monitoring Goes Wireless. *Pharm Form Quality.* Nov.:43-47
- Otondo, W. 2005. Environmental Monitoring Goes Wireless. *Contamination Control.* 1(1):48-50
- Ronholdt, C./Bogdansky, S.. 2005. The Appropriateness of Swab Cultures for the Release of Human Allograft Tissue. *J Ind Microbiol Biotechnol.* 32:349 - 354
- Westney, R. 2005. Strategies for Managing Environmental Monitoring Investigations. *Amer Pharm Rev.* 8(4):18-31

#### Filtration

- Brorson, K *et al.* 2005. "Large Pore Size" Virus Filter Test Method Recommended by the PDA Virus Filter Task Force. *PDA J Pharm Sci Tech.* 59(3):177-186
- Brorson, K *et al.* 2005. Nomenclature Standardization for 'Large Pore Size' Virus-Retentive Filters. *PDA J Pharm Sci Tech.* 59(6):341-345
- Cardona, M.. 2005. Considerations for Buffer *Contamn Control.* June/July:28 - 31
- Graham, M. *et al.* 2005. Low Rates of Cutaneous Adverse Reactions to Alcohol-Based Hand Hygiene Solution during Prolonged Use in a Large Teaching Hospital. *Antimicrob Agents Chemother.* 49(10):4404-4405
- Handwashing
- Handwashing. Kampf, G./Ostermeyer, C.. 2005. Efficacy of Two Distinct Ethanol-Based Hand Rubs for Surgical Hand Disinfection - A Controlled Trial According to prEN 12791. *BMC Infect Dis.* 5(17):1 - 4
- Hibbard, J.. 2005. Analyses Comparing the Antimicrobial Activity and Safety of Current Antiseptic Agents: A Review. *J Infusion Nursing.* 28(3):194 - 207
- Jornitz, MW *et al.* 2005. Choosing the Appropriate Membrane Filter - Test Requirements. *PDA J Pharm Sci Tech.* 59(2):96-101
- Kampf, G., Grotheer, D., *et al.* 2005. Efficacy of Three Ethanol-Based Hand Rubs Against Feline Calicivirus, a Surrogate Virus for

- Norovirus. *J Hosp Infect.* 60:144 - 149
- Kampf, G., Ostermeyer C., *et al.* 2005. Surgical Hand Disinfection with a Propanol-Based Hand Rub: Equivalence of Shorter Application Times. *J Hosp Infect.* 59:304 - 310
- PDA. 2005. PDA Tech Report #40: Sterilizing Filtration of Gases. . . . .
- PDA. 2005. PDA Tech Report #41: Virus . . . . .
- Pedersen, L., Held, E., *et al.* 2005. Less Skin Irritation From Alcohol-Based Disinfectant than from Detergent Used for Hand Disinfection. *Brit J Dermatology.* 153:1142 - 1146
- Tvedt, C./Bukholm, G.. 2005. Alcohol-Based Hand Disinfection: A More Robust Hand-Hygiene Method in an Intensive Care Unit. *J Hosp Infect.* 59:229 - 234

#### Identification

- Adams, D., Gurr, S., *et al.* 2005. Cellular Fatty-Acid Analysis of *Bacillus Thuringiensis* Var. *Kurstaki* Commercial Preparations. *J Agric Food Chem.* 53:512 - 517
- Adley, C./Saieb, F.. 2005. Comparison of bioMérieux API 20NE and Remel RapID NF Plus, Identification Systems of Type Strains of *Ralstonia pickettii*. *Lett Appl Microbiol.* 41:136 - 140
- Ahmed, W., Neller, R., *et al.* 2005. Evidence of Septic Systems Failure Determined by a Bacterial Biochemical Fingerprinting Method. *J Appl Microbiol.* 98:910 - 920
- Ben-Amor, K *et al.* 2005. Genetic Diversity of Viable, Injured, and Dead Fecal Bacteria Assessed by Fluorescence-Activated Cell Sorting and 16S rRNA Gene Analysis. *Appl Environ Microbiol.* 71(8):4679-4689
- Bruins, MJ and MJHM Wolfhagen. 2005. Nonfermenters under the Influence: Ethanol Disinfection of a Saline Dispenser Caused Misidentification by the Vitek 2 System Using the New GN Cards. *J Clin Microbiol.* 43(8):4296-4297
- Cliff, JB *et al.* 2005. Differentiation of Spores of *Bacillus subtilis* Grown in Different Media by Elemental Characterization Using Time-of-Flight Secondary Ion Mass Spectrometry. *Appl Environ Microbiol.* 71(11):6524-6530
- Conbille, P. and Witebsky, F.. 2005. Multiple Copies of the 16S rRNA Gene in *Nocardia Nova* Isolates and Implications for Sequence-Based Identification Procedures. *J Clin Microbiol.* 43 (6):2881 - 2885
- DeCory, TR *et al.* 2005. Development of an Immunomagnetic Bead-Immunoliposome Fluorescence Assay for Rapid Detection of *Escherichia coli* O157:H7 in Aqueous Samples and Comparison of the Assay with a Standard Microbiological Method. *Appl Environ Microbiol.* 71

(Continued on page 14)

(Continued from page 13)

- (4):1856-1864
- Dewhirst, FE *et al.* 2005. Discordant 16S and 23S rRNA Gene Phylogenies for the Genus *Helicobacter*: Implications for Phylogenetic Inference and Systematics. *J Bacteriol.* 187(17):6106-6118
- Drancourt, M. and D. Raoult. 2005. Sequence-Based Identification of New Bacteria: a Proposition for Creation of an Orphan Bacterium Repository. *J Clin Microbiol.* 43 (9):4311-3215
- Duran, M., Haznedaroğlu<sup>a</sup>, B., *et al.* 2005. Microbial source tracking using host specific FAME profiles of fecal coliforms. *Water Research.* 40:67 - 74
- Ecker, DJ *et al.* 2005. Rapid identification and strain-typing of respiratory pathogens for epidemic surveillance. *PNAS.* 102 (22):8012-8017
- Eigner, U *et al.* 2005. Analysis of the Comparative Workflow and Performance Characteristics of the VITEK 2 and Phoenix Systems. *J Clin Microbiol.* 43(8):3829-3834
- Eigner, U., Fahr, A., *et al.* 2005. Evaluation of a New Molecular System for Simultaneous Identification of Four Enterococcus Species and Their Glycopeptide Resistance Genotypes. *J Clin Microbiol.* 43(6):2920 - 2922
- Fontana, C *et al.* 2005. Use of the MicroSeq 500 16S rRNA Gene-Based Sequencing for Identification of Bacterial Isolates That Commercial Automated Systems Failed To Identify Correctly. *J Clin Microbiol.* 43(2):615-619
- Funke, G and P Funke-Kissling. 2005. Performance of the New VITEK 2 GP Card for Identification of Medically Relevant Gram-Positive Cocci in a Routine Clinical Laboratory. *J Clin Microbiol.* 43(1):84-88
- Gafan, GP *et al.* 2005. Statistical Analyses of Complex Denaturing Gradient Gel Electrophoresis Profiles. *J Clin Microbiol.* 43 (8):3971-3978
- George, BJ *et al.* 2005. Effect of Inoculum Size on Detection of *Candida* Growth by the BACTEC 9240 Automated Blood Culture System Using Aerobic and Anaerobic Media. *J Clin Microbiol.* 43(1):433-435
- Giammarinaro, P., Leroy, S., *et al.* 2005. Development of a New Oligonucleotide Array to Identify Staphylococcal Strains at Species Level. *J Clin Microbiol.* 43(8):3673 - 3680
- Green, SJ and D Minz. 2005. Suicide Polymerase Endonuclease Restriction, a Novel Technique for Enhancing PCR Amplification of Minor DNA Templates. *Appl Environ Microbiol.* 71(8):4721-4727
- Haarman, M and J Knol. 2005. Quantitative Real-Time PCR Assays To Identify and Quantify Fecal Bifidobacterium Species in Infants Receiving a Prebiotic Infant Formula. *Appl Environ Microbiol.* 71(5):2318-2324
- Hassan, WM *et al.* 2005. Methods To Increase Fidelity of Repetitive Extragenic Palindromic PCR Fingerprint-Based Bacterial Source Tracking Efforts. *Appl Environ Microbiol.* 71 (1):512-518
- Healy, M *et al.* 2005. Microbial DNA Typing by Automated Repetitive-Sequence-Based PCR. *J Clin Microbiol.* 43(1):199-207
- Heikens, E. *et al.* 2005. Comparison of Genotypic and Phenotypic Methods for Species-Level Identification of Clinical Isolates of Coagulase-Negative Staphylococci. *J Clin Microbiol.* 43(5):2286-2290
- Hsiao, C., *et al.* 2005. Identification of Medically Important Molds by an Oligonucleotide Array. *J Clin Microbiol.* 43(8):3760 - 3768
- Hunter, SB *et al.* 2005. Establishment of a Universal Size Standard Strain for Use with the PulseNet Standardized Pulsed-Field Gel Electrophoresis Protocols: Converting the National Databases to the New Size Standard. *J Clin Microbiol.* 43(3):1045-1050
- Huys, G *et al.* 2005. Molecular Diversity and Characterization of Tetracycline-Resistant *Staphylococcus aureus* Isolates from a Poultry Processing Plant. *Appl Environ Microbiol.* 71(1):574-579
- Kanemitsu, K., Kunishima, H., *et al.* 2005. Assessment of RAISUS, a novel system for identification and antimicrobial susceptibility testing for enterococci. *Diagn Microbiol Infect Dis.* 53:23 - 27
- Kobayashi, N., *et al.* 2005. A Molecular Gram Stain Using Broad Range PCR and Pyrosequencing Technology. *Diagn Mol Pathol.* 14 (2):83 - 89
- Konstantinidis, KT and JM Tiedje. 2005. Towards a Genome-Based Taxonomy for Prokaryotes. *J Bacteriol.* 187(18):6258-6264
- Kwon, H., Yang, E., *et al.* 2005. Rapid Identification of Potentially Probiotic Bifidobacterium Species by Multiplex PCR Using Species-Specific Primers Based on the Region Extending from 16S rRNA through 23S rRNA. *FEMS Microbiol Lett.* 250:55 - 62
- Mateo, M., Maestre, J., *et al.* 2005. Genotypic Versus Phenotypic Characterization, with Respect to Susceptibility and Identification, of 17 Clinical Isolates of *Staphylococcus lugdunensis*

(Continued on page 15)

(Continued from page 14)

- nensis. *J Antimicrob Chemother.* 56:287 - 291
- Morandi, A *et al.* 2005. Evolutionary and Diagnostic Implications of Intragenomic Heterogeneity in the 16S rRNA Gene in *Aeromonas* Strains. *J Bacteriol.* 187(18):6561–6564
- Ogawa, M., Tani, K., *et al.* 2005. Multicolour digital image analysis system for identification of bacteria and concurrent assessment of their respiratory activity. *J Appl Microbiol.* 98:1101 - 1106
- O'Hara, CM. 2005. Manual and Automated Instrumentation for Identification of Enterobacteriaceae and Other Aerobic Gram-Negative Bacilli. *Clin Microbiol Rev.* 18(1):147-162
- Pernthaler, J and R Amann. 2005. Fate of Heterotrophic Microbes in Pelagic Habitats: Focus on Populations. *Microbiol Mol Biol Rev.* 69 (3):440-461
- Sapp, J. 2005. The Prokaryote-Eukaryote Dichotomy: Meanings and Mythology. *Microbiol Mol Biol Rev.* 69(2):306-325
- Schutt, CK *et al.* 2005. Clinical Evaluation of the DiversiLab Microbial Typing System Using Repetitive-Sequence-Based PCR for Characterization of *Staphylococcus aureus* Strains. *J Clin Microbiol.* 43(3):1187-1192
- Shutt, CK *et al.* 2005. Clinical Evaluation of the DiversiLab Microbial Typing System Using Repetitive-Sequence-Based PCR for Characterization of *Staphylococcus aureus* Strains. *J Clin Microbiol.* 43(3):1187-1192
- Sogaard, M *et al.* 2005. Direct Identification of Major Blood Culture Pathogens, Including *Pseudomonas aeruginosa* and *Escherichia coli*, by a Panel of Fluorescence In Situ Hybridization Assays Using Peptide Nucleic Acid Probes. *J Clin Microbiol.* 43(4):1947-1949
- Sorlózano, A., Gutiérrez, J., *et al.* 2005. Acceptable Performance of VITEK 2 System to Detect Extended-Spectrum  $\beta$ -Lactamases in Clinical Isolates of *Escherichia coli*: A Comparative Study of Phenotypic Commercial Methods and NCCLS Guidelines. *Diagn Microbiol Infect Dis.* 51:191 - 193
- Valentine, N *et al.* 2005. Effect of Culture Conditions on Microorganism Identification by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry. *Appl Environ Microbiol.* 71(1):58-64
- Wallet, F *et al.* 2005. Performances of VITEK 2 Colorimetric Cards for Identification of Gram-Positive and Gram-Negative Bacteria. *J Clin Microbiol.* 43(9):4402-4409
- Wellinghausen, N *et al.* 2005. Superiority of Mo-

lecular Techniques for Identification of Gram-Negative, Oxidase-Positive Rods, Including Morphologically Nontypical *Pseudomonas aeruginosa*, from Patients with Cystic Fibrosis. *J Clin Microbiol.* 43(8):4070-4075

### Preservatives

- Jeffries, N.. 2005. Natural Preservatives Gain Ground. *Global Cosmetic Indust.* Aug:48 - 49
- Selvaraju, SB *et al.* 2005. Biocidal Activity of Formaldehyde and Nonformaldehyde Biocides toward *Mycobacterium immunogenum* and *Pseudomonas fluorescens* in Pure and Mixed Suspensions in Synthetic Metalworking Fluid and Saline. *Appl Environ Microbiol.* 71(1):542-546
- Thomas, L., Russell, A., *et al.* 2005. Antimicrobial activity of chlorhexidine diacetate and benzalkonium chloride against *Pseudomonas aeruginosa* and its response to biocide residues. *J Appl Microbiol.* 98(.):533 - 543
- Turner, NA *et al.* 2005. Resistance, Biguanide Sorption and Biguanide-induced Pentose Leakage During Encystment of *Acanthamoeba castellanii*. *J Appl Microbiol.* 96:1287-1295
- Williams, J.. 2005. The N-Halamine Suit of Armor. *Contamn Control.* June/July:38 - 39

### Rapid Methods

- Adler, H., Straub, C., *et al.* 2005. Comparison of Bact/ALERT 3D, Lowenstein-Jensen medium and Middlebrook 7H10/7H11 biplate for recovering mycobacteria from clinical specimens. *Eur J Clin Microbiol Infect Dis.* 24:499 - 500
- Baudart, J., Olaizola, A., *et al.* 2005. Assessment of a New Technique Combining a Viability Test, Whole-Cell Hybridization and Laser-Scanning Cytometry for the Direct Counting of Viable Enterobacteriaceae Cells in Drinking Water. *FEMS Microbiol Lett.* 243:405 - 409
- Bolotin, C. 2005. Instantaneous Microbial Detection. *Controlled Environments.* 8(12):10-15
- Cobo, F., Stacey, G., *et al.* 2005. Microbiological Control in Stem Cell Banks: Approaches to Standardisation. *Appl Microbiol Biotechnol.* 68:456 - 466
- Delgado-Viscogliosi, P., T Simonart *et al.* 2005. Rapid Method for Enumeration of Viable *Legionella pneumophila* and Other *Legionella* ssp. In Water. *Applied and Environmental Microbiology.* 71(7):4086 - 4096
- Dionne, K *et al.* 2005. Methods for Reducing Bacterial Contamination in the Bact/Alert Mycobacterial Culture Detection System. *J Clin Microbiol.* 43(5):2523-2525

(Continued on page 16)

(Continued from page 15)

- Dunn, GM. 2005. Listeria Detection, Isolation and Confirmation. *Food Quality*. Feb/March:46-50
- Fujino, M, Yoshida, N., *et al.* 2005. A Simple Method for the Detection of Measles Virus Genome by Loop-Mediated Isothermal Amplification (LAMP). *J Med Virology*. 76:406 - 413
- Habbal, W., *et al.* 2005. Errors in Published Sequences of Human Cytomegalovirus Primers and Probes: Do We Need More Quality Control? ( Letters to the Editor). *J Clin Microbiol*. 43(10):5408 - 5409
- Hoefel, D *et al.* 2005. Culture-Independent Techniques for Rapid Detection of Bacteria Associated with Loss of Chloramine Residual in a Drinking Water System. *Appl Environ Microbiol*. 71(11):6479–6488
- Horz, H., *et al.* 2005. Evaluation of Universal Probes and Primer Sets for Assessing Total Bacterial Load in Clinical Samples: General Implications and Practical Use in Endodontic Antimicrobial Therapy. *J Clin Microbiol*. 43 (10):5332 - 5337
- Jervøe-Storm P, Koltzschler, M., *et al.* 2005. Comparison of 'culture and Real-Time PCR for Detection and Quantification of Five Putative Periodontopathogenic Bacteria in Subgingival Plaque Samples. *J Clin Periodontology*. 32:778 - 783
- Kitaguchi, A *et al.* 2005. Enumeration of Respiring Pseudomonas spp. in Milk within 6 Hours by Fluorescence In Situ Hybridization following Formazan Reduction. *Appl Environ Microbiol*. 71(5):2748-2752
- Koroneos, G.. 2005. Validating Automated Systems. *Pharm Technol*. 29(3):42 - 44
- Kressner, A.. 2005. Pushing the Microbiology Envelope. *Contamn Control*. Fall:50
- Kühl, M.. 2005. Optical Microsensors for Analysis of Microbial Communities. *Methods In Enzymology*. 397:166 - 199
- Leinberger, D., *et al.* 2005. Development of a DNA Microarray for Detection and Identification of Fungal Pathogens Involved in Invasive Mycoses. *J Clin Microbiol*. 43(10):4943 - 4953
- McDaniel, A.. 2005. Microbial Detection in Mammalian Cell Culture Systems. *Eur Pharm Rev*. 11(4):94 - 98
- Miller, MJ. 2005. Rapid Microbiological Methods and FDA's Initiatives for Pharmaceutical cGMP's for the 21st Century, PAT and Sterile Drug Products Produced by Aseptic Processing. *Amer Pharm Rev*. 8(1):104-107
- Nakajima, K., Nonaka, K., *et al.* 2005. Rapid monitoring of microbial contamination on herbal medicines by fluorescent staining method. *Lett Appl Microbiol*. 40:128 - 132
- Newby, P.. 2005. Implementation, Validation and Registration. *Eur Pharm Rev*. 11(2):92 - 96
- Peleg, M., Normand, M., *et al.* 2005. Generating Microbial Survival Curves During Thermal Processing in Real Time. *J Appl Microbiol*. 98:406 - 417
- Rudensky, B., Broidie, E., *et al.* 2005. Rapid Flow-Cytometric Susceptibility Testing of Candida Species. *J Antimicrob Chemother*. 55:106 - 109
- Rueckert, A., Ronimus, R., *et al.* 2005. Development of a Rapid Detection and Enumeration Method for Thermophilic Bacilli in Milk Powders. *J Microbiol Methods*. 60:155 - 167
- Sakamoto, C., Yamaguchi, N., *et al.* 2005. Rapid and Simple Quantification of Bacterial Cells by Using a Microfluidic Device. *Appl Environ Microbiol*. 71(2):1117 - 1121
- Shintani, T., Torimura, M., *et al.* 2005. Rapid Separation of Microorganisms by Quartz Microchip Capillary Electrophoresis. *Analy Sciences*. 21:57 - 60
- Stoughton, R.. 2005. Applications of DNA Microarrays in Biology. *Ann Rev Biochem*. 74:53 - 82
- Sutton, SVW. 2005. Validation of Alternative Microbiology Methods for Product Testing: Quantitative and Qualitative Assays. *Pharm Technol*. 29(4):118-122
- USP. 2005. <1058> Analytical Instrument Qualification. *Pharm Forum*. 31(1):233-243
- USP. 2005. <1058> Analytical Instrument Qualification. *Pharm Forum*. 31(1):233-243
- USP. 2005. <1223> Validation of Alternative Microbiological Methods. *Pharm Forum*. 31 (5):1475-1486
- USP. 2005. <1225> Validation of Compendial Methods IN-PROCESS REVISION. *Pharm Forum*. 31(2):549-555
- USP. 2005. <1226> Verification of Compendial Procedures IN-PROCESS REVISION. *Pharm Forum*. 31(2):555-558
- van de Goor, TA. 2005. A History of DNA Microarrays. *Pharm Discovery*. 5(7):42-45
- Weschler, T.. 2005. "I need the results and I need them now!". *Pharm Formul & Quality*. June/July:78-80
- Weschler, T. 2005. I Need Results and I Need Them Now!. *Food Quality*. Dec/Jan:24-25
- Wiles, S *et al.* 2005. Alternative Luciferase for Monitoring Bacterial Cells under Adverse Conditions. *Appl Environ Microbiol*. 71(7):3624–3632
- Yvon, P. 2005. Proactive Response to Airborne Contamination. *Pharm Form Quality*. Oct.:66-70

(Continued on page 17)



(Continued from page 16)

Zayas, J *et al.* 2005. Analytical Methods Validation: In-Process Control Methods for the Manufacture of Active Pharmaceutical Ingredients. *Pharm Technol.* 29(4):154-162

### Risk Assessment

Bartholomew, MJ *et al.* 2005. A Linear Model For Managing The Risk of Antimicrobial Resistance Originating In Food Animals. *Risk Anal.* 25(1):99-108

Cox, L./Ricci P.. 2005. Causation in Risk Assessment and Management: Models, Inference, Biases, and a Microbial Risk-Benefit Case Study. *Environment Int.* 31:377 - 397

Gaylor, David W. 2005. Risk/Benefit Assessments of Human Diseases: Optimum Dose For Intervention. *Risk Anal.* 25(1):161-8

Goldstein, B.. 2005. Advances in Risk Assessment and Communication. *Ann Rev Public Health.* 26:141 - 163

Koutsoumanis, K *et al.* 2005. Development of A Safety Monitoring and Assurance System For Chilled Food Products. *Int J Food Microbiol.* 100(1-3):253-60

Marks, HM and ME Coleman. 2005. Accounting For Inherent Variability of Growth In Microbial *Int J Food Microbiol.* 100(1-3):275-87

Nauta, M *et al.* 2005. A Poultry-Processing Model For Quantitative Microbiological *Risk Anal.* 25(1):85-98

Parsons, DJ *et al.* 2005. A Comparison of Three Modelling Approaches For Quantitative Risk Assessment Using The Case Study of *Salmonella* Spp. In Poultry Meat. *Int J Food Microbiol.* 98(1):35-51

Robertson, B./Nicholson, J.. 2005. New Microbiology Tools for Public Health and Their Implications. *Ann Rev Public Health.* 26:281 - 302

### Sterilization

Caputo, R., Reich, R., *et al.* 2005. VHP; The Sterilant of Choice. *Contamn Control.* June/July:20 - 23

Celine, B *et al.* 2005. Permeation Risks with Peracetic Acid and Hydrogen Peroxide Sterilizing Agent Inside Ambulatory Pumps. *PDA J Pharm Sci Tech.* 59(3):200-205

Czarneski, MA and P Poisson. 2005. Chlorine Dioxide Gas Decontamination of a Blow/Fill/Seal Machine. *A2C2.* 8(4):10-15

DeSorbo, M.. 2005. The Next Frontier: Vaporized Hydrogen Peroxide. *Contamn Control.* June/July:18 - 23

EMA. 2005. Concept Paper on the Development of a Guideline on Parametric Release. *EMA.*

Harvard, L *et al.* 2005. Evaluation of Peracetic Acid Permeation during Flash Sterilization through Pharmaceutical Plastic Polymers Used in Cytotoxic Reconstitution Units. *PDA J Pharm Sci Tech.* 59(4):258-264

Kort, R *et al.* 2005. Assessment of Heat Resistance of Bacterial Spores from Food Product Isolates by Fluorescence Monitoring of Dipicolinic Acid Release. *Appl Environ Microbiol.* 71(7):3556–3564

Leguerinel, I., Spegagne, I., *et al.* 2005. Validation of an overall model describing the effect of three environmental factors on the apparent D-value of *Bacillus cereus* spores. *Intl J Food Microbiol.* 100:223 - 229

Mosley, GA *et al.* 2005. Evaluating the Formulae for Integrated Lethality in Ethylene Oxide Sterilization Using Six Different Endospore Forming Strains of Bacteria, and Comparisons of Integrated Lethality for Ethylene Oxide and Steam Systems. *PDA J Pharm Sci Tech.* 59(1):64-86

Pflug, IJ. 2005. Variability in the Data Generated by Laboratories Measuring D-values of Bacterial Spores. *PDA J Pharm Sci Tech.* 59(1):3-9

Reich, R and RA Caputo. 2005. The Adverse Effects of Cellulosic Material in Isolator Barrier Technology. *Pharm Technol.* 29(11):52-58

Reich, R *et al.* 2005. Global Sterilization: Making the Standards Standard. *Med Device Diag Indust.* 27(3):78-91

Rudge, S.. 2005. Say Clean with Steam. *Contamn Control.* Fall:34 - 36

Tirumalaie, R and D Porter. 2005. Terminal Sterilization and Potential for Parametric Release. *Amer Pharm Rev.* 8(4):26-31

### Tests, Finished Product

Ayorinde, J., Odeku, O., *et al.* 2005. The Survival of *B. Subtilis* Spores in Dicalcium Phosphate, Lactose, and Corn Starch. *Pharm Technol.* 29(12):56 - 67

Byrne, DD. 2005. Validation of Sterility Test Isolators. *Amer Pharm Rev.* 8(1):30-37

Cundell, AM. 2005. Managing the Microbiological Quality of Pharmaceutical Excipients. *PDA J Pharm Sci Tech.* 59(6):383-395

Depyrogenation. Moesby, *et al.* 2005. Dry and Moist Heat Sterilisation Cannot Inactivate Pyrogenicity of Gram Positive Microorganisms. *Eur J Pharm Sci.* 26:318 - 323

Hoffmann, S., *et al.* 2005. International Validation of Novel Pyrogen Test Based on Human Monocytoid Cells. *J Immunol Meth.* 298:161 - 173

Madden, J. 2005. Screening Raw Material for Microbial Contamination. *Pharm Form Quality.*

(Continued on page 18)

(Continued from page 17)

Oct.:46-51

- Muniesa, M *et al.* 2005. Bacteriophages May Bias Outcome of Bacterial Enrichment Cultures. *Appl Environ Microbiol.* 71(8):4269–4275
- Park, C.. 2005. Comparison of the Rabbit Pyrogen Test and Limulus Amoebocyte Lysate (LAL) Assay for Endotoxin in Hepatitis B Vaccines and the Effect of Aluminum Hydroxide. *Biologicals.* 33:145 - 151
- Priano, G./Battaglini, F.. 2005. Use of an Antimicrobial Protein for Endotoxin Detection in a Competitive Electrochemical Assay. *Anal Chem.* 77:4976 - 4984
- Schroeder, HG. 2005. Sterility Failure Analysis. *PDA J Pharm Sci Tech.* 59(2):89-95
- Szathmary, S. 2005. Endotoxin in Parenteral Medicines may be a Risk Factor in Severe Sepsis. *PDA J Pharm Sci Tech.* 59(4):240-245
- USP Project Team 7. 2005. Microbial Testing for Orally Inhaled and Nasal Drug Products. *Pharm Forum.* 31(4):1258-1261

### Training

- Hoeltge, GA *et al.* 2005. Detection and Correction of Systematic Laboratory Problems by Analysis of Clustered Proficiency Testing Failures. *Arch Pathol Lab Med.* 129:186-189
- Prior, Z., *et al.* 2005. Lenticule Discs Provide a Homogenous Format for External Quality Assessment Samples: A Comparison with Freeze-Dried Samples for Shellfish Microbiology. *Lett Appl Microbiol.* 41:334 - 340
- Sartain, EK. 2005. Designing a Results-Oriented Training Program for Cleanroom Operators. *Controlled Environments.* 8(10):20-24
- Schaechter, M *et al.* 2005. Microbiology Happens. *ASM News.* 71(2):54-55
- Weiss, CA and S Rabauer. 2005. Trials and Tribulations Behind Training Initiatives. *Pharm Formul Qual.* Aug/Sept:64-65

### Water

- Fontana, A./Mumford, J.. 2005. Incorrect Water Measurements Costly. *Pharm Formul & Quality.* Nov:63 - 66
- Gonzalez, M.. 2005. Materials of Construction for Biopharmaceutical Water Systems, Part 1. *Amer Pharm Rev.* 8(3):79 - 85
- Hamilton, W. *et al.* 2005. Comparison of Commercially Available Escherichia coli Enumeration Tests: Implications for Attaining Water Quality Standards. *Water Research.* 39:4869 - 4878
- Hijnen, W., Beerendonk, E., *et al.* 2005. Inactivation credit of UV radiation for viruses, bacteria and protozoan (oo)cysts in water: A review. *Water Research.* 40:3 - 22

- Hill, VR *et al.* 2005. Development of a Rapid Method for Simultaneous Recovery of Diverse Microbes in Drinking Water by Ultrafiltration with Sodium Polyphosphate and Surfactants. *Appl Environ Microbiol.* 71(11):6878–6884
- King, M. 2005. Selection Criteria for WFI Production Equipment. *Controlled Environments.* 8(9):10-15
- Lasalde, C *et al.* 2005. Statistical Analyses: Possible Reasons for Unreliability of Source Tracking Efforts. *Appl Environ Microbiol.* 71(8):4690–4695
- Loy, A *et al.* 2005. Diversity of Bacteria Growing in Natural Mineral Water after Bottling. *Appl Environ Microbiol.* 71(7):3624–3632
- Murphy, S., Norris, M., *et al.* 2005. Laboratory Water Challenges. *Contamn Control.* Fall:26 - 28
- Murphy, S., Norris, M., *et al.* 2005. Laboratory Water Challenges. *Pharm Formul & Quality.* Aug/Sept:68 - 71
- Nesdore, P./Mcleod, R.. 2005. Laboratory Water Systems - An Overview. *A2C2.* 8(6):24 - 26
- Oliver, J.. 2005. The Viable but Nonculturable State in Bacteria. *J Microbiology.* 43(S):93 - 100
- Perez, A., Hohn, C., *et al.* 2005. Filtration methods for recovery of *Bacillus anthracis* spores spiked into source and finished *Water Research.* 39:5199 - 5211
- Rice, EW *et al.* 2005. Inactivation of Spores of *Bacillus anthracis* Sterne, *Bacillus cereus*, and *Bacillus thuringiensis* subsp. *israelensis* by Chlorination. *Appl Environ Microbiol.* 71(9):5587-5589
- Rose, LJ. 2005. Chlorine Inactivation of Bacterial Bioterrorism Agents. *Appl Environ Microbiol.* 71(1):566–568
- Schraft H; Watterworth L A . 2005. Enumeration of heterotrophs, fecal coliforms and *Escherichia coli* in water: comparison of 3M Petrifilm plates with standard plating procedures. *J Microbiol Meth.* 60(3):335-342
- Torres, G *et al.* 2005. Comparison of EP “Heavy Metals” Test with USP “Conductivity” Test. *Pharm Technol.* Jan:80-82
- USP. 2005. <1230> Water for Health Applications. *Pharm Forum.* 31(5):1486
- Vaerewijck, M., Huys, G., *et al.* 2005. Mycobacteria in drinking water distribution systems: ecology and significance for human health. *FEMS Microbiol Rev.* 29:911 - 934

### Water Activity

- Fontana, A.. 2005. Sample Preparation for Water Activity Analysis. *Pharm Formul & Quality.* Aug/Sept:66 - 68
- Laroche, C., Fine, F., *et al.* 2005. Water Activity Affects Heat Resistance of Microorganisms in Food Powders. *Int J Food Microbiol.* 97:307 - 315
- O'Brien, J.. 2005. Hygrometer History. *Pharm Formul & Quality.* Nov:56-58